How DIR fees actually work — and where the 9% clawback figure comes from

Direct and Indirect Remuneration fees — DIR fees for short — are the single largest source of margin compression facing independent pharmacies in 2026. And they are also the most structurally confusing, because they operate across three separate layers: the Medicare Part D statutory framework, the PBM contract you signed, and the CMS performance scoring system that drives the retroactive calculations.

This article breaks down how DIR fees actually work, where the widely-cited "9% of gross dispensing revenue" figure comes from, and what the 2022 point-of-sale reform changed — and more importantly, what it did not change.

The original design versus the current reality

DIR fees were introduced as part of Medicare Part D in 2003. The original concept was narrow: any price concession, rebate, or adjustment applied to a prescription drug transaction after the point of sale needed to be reported to CMS, so that Medicare could calculate the true net cost of the drug benefit.

Over time, PBMs expanded the category. What began as a reporting mechanism became a network participation fee. Then it became a performance-based assessment tied to quality metrics. By 2018, independent pharmacy associations were reporting that DIR fees had grown from a minor accounting line to a material percentage of gross dispensing revenue — in some cases reaching 9% or higher across a pharmacy's Medicare Part D claims.

The structural change was not in the law. It was in the contracts. PBM provider manuals added performance-based DIR clauses, retroactive true-up mechanisms, and reconciliation schedules that allowed fees to be assessed months after the original claim was paid.

The four forms DIR fees take today

If you subscribe to Independent Pharmacy Audit Clarity, you know we spend significant time translating DIR statements because they rarely label the fees clearly. Most PBMs use one or more of these four structures:

Flat per-claim fees. A fixed dollar amount deducted from every Medicare Part D claim, usually assessed quarterly. This is the simplest form and the easiest to model.

Percentage-of-ingredient-cost fees. A percentage — often between 1.5% and 5% — calculated against the ingredient cost of each claim. These compound over time because they scale with drug pricing.

Performance-based fees. Variable fees tied to pharmacy quality metrics including adherence rates for diabetes, statins, and hypertension medications; generic dispensing rates; and measures derived from CMS Star Ratings. Pharmacies that underperform on these metrics pay higher fees.

Reconciliation fees. Retroactive true-up assessments that reconcile what the PBM actually earned from Medicare against what was projected. These can be assessed annually or semi-annually and are often the largest single line on a DIR statement.

Where the 9% figure comes from

Studies from the Community Oncology Alliance, the National Community Pharmacists Association, and multiple state pharmacy boards have consistently found that combined DIR fees can reach 9% of gross Medicare Part D dispensing revenue for independent pharmacies. The figure is not a cap and it is not a typical rate. It is the upper bound observed in documented cases.

For a pharmacy dispensing $2 million in Medicare Part D claims annually, a 9% effective DIR rate means $180,000 in annual clawbacks — usually spread across quarterly reconciliation cycles, which makes cash flow planning nearly impossible.

The 2022 CMS reform and what it actually changed

In May 2022, CMS finalized a rule requiring that "all price concessions from network pharmacies" be reflected at the point of sale, effective January 1, 2024. This was widely reported as "the end of retroactive DIR fees."

That framing was incomplete. The rule required that pharmacy price concessions be reflected in the negotiated price at the point of sale — meaning the patient's cost-sharing obligation would be calculated against a lower net price. But the rule did not prohibit PBMs from assessing performance-based fees after dispensing. It shifted the timing of certain fees into the pre-sale calculation while leaving performance-based assessments structurally intact.

The 2024 implementation produced two predictable effects. First, pharmacies saw lower upfront reimbursement per claim because the point-of-sale price now reflected anticipated concessions. Second, PBMs shifted more fee structures into performance-based categories that remained assessable after dispensing.

Why performance metrics became the audit battleground

If you read a 2026 DIR statement carefully, you will notice that the largest variable component is almost always tied to performance metrics. Adherence scores. Star Ratings. Generic dispensing percentages. The reason is structural: post-reform, these are the categories that still support retroactive fee assessment.

The problem for independent pharmacies is that the metrics are largely outside your control. Patient adherence is driven by patient behavior, insurance formulary changes, and prescriber habits — not by anything your pharmacy can influence at the counter. But DIR calculations treat these metrics as if they were operational outputs your pharmacy manages.

This is why PBMs also use performance thresholds as triggers for deeper audit exposure. A pharmacy that falls below a specific adherence benchmark often receives not just a higher DIR fee, but also an expanded audit scope. The connection is rarely explained in the initial statement.

What to look for on your next DIR statement

When a DIR fee statement arrives, focus on four things. First, the assessment period — which quarter or month of claims is being reconciled. Second, the breakdown by category — flat fees versus performance-based versus reconciliation. Third, the specific performance thresholds cited — which metrics, measured against which benchmarks, during which window. Fourth, the calculation basis — whether the fee is assessed against gross claims, ingredient cost, or a negotiated rate.

If any of those four are unclear from the statement itself, that is not a reading-comprehension problem. It is a structural opacity problem that affects every independent pharmacy in every network. Ask the PBM for the calculation methodology in writing. Most provider manuals technically require disclosure on request, even if PBMs rarely volunteer it.